Orchard Plans EU Submission For GSK-Originated MLD Gene Therapy
Orchard is aiming to get its second autologous gene therapy on the market next year, with a European filing for MLD and a BLA to follow.
You may also be interested in...
Milan, Italy is a hotspot in Europe for gene therapy research, and the European VC Sofinnova Partners is backing the latest start-up aimed at metabolic and primary immunodeficiencies.
Orchard Therapeutics will acquire GSK’s portfolio of approved and investigational rare disease gene therapies, including EU-approved Strimvelis and additional late-stage gene therapies.
Decades after it was first mentioned, the updated European patent system – which includes the Unitary Patent and the Unified Patent Court – has finally materialized. What impact will this have on originator and generic pharma?